Fulcrum Therapeutics Q3 net loss $23.7M; cash $221.8M; selected 12mg dose for FTX-6058 SCD trial

Fulcrum Therapeutics, Inc.

2022-Q3 EPS reported -$1.97 revenue$5,657,000

Net loss $23.7M vs $20.7M year ago; collaboration revenue fell to $1.2M from $4.9M due to Acceleron wind-down.
Cash, equivalents, and marketable securities $221.8M; cash runway guidance extended into late 2024.
Completed equity raise of ~$80.8M net proceeds in August 2022.
Selected 12mg as dose for next FTX-6058 Phase 1b cohort in sickle cell disease; enrollment continues.
Appointed Santiago Arroyo as CMO and Jeff Jacobs as CSO; losmapimod Phase 3 REACH trial enrollment ongoing.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Fulcrum Therapeutics, Inc. reported the third quarter of 2022 results: revenue $1.2 million, net income Net loss was $23.7 million.

Period: the third quarter of 2022
Revenue: $1.2 million
Net income: Net loss was $23.7 million
Result: reported results

Exact text from the filing

Third Quarter 2022 Financial Results • Cash Position: As of September 30, 2022, cash, cash equivalents, and marketable securities were $221.8 million as compared to $218.2 million as of December 31, 2021. The increase in cash is primarily tied to our equity offering in August 2022, partially offset by our net cash used in operating activities. • Collaboration Revenue: Collaboration revenue was $1.2 million for the third quarter of 2022 as compared to $4.9 million for the third quarter of 2021. The decrease of $3.7 million was primarily due to the winding down of Fulcrum's collaboration agreement with Acceleron Pharma Inc., a wholly owned subsidiary of Merck & Co., Inc. • Operating Expenses: Total operating expenses were $25.5 million for the third quarter of 2022 as compared to $25.7 million for the third quarter of 2021. A decrease of $1.7 million in R&D expenses was primarily due to reduced discovery and external research and development costs. This was partially offset by an increas

View on SEC.gov

Browse all earnings releases →

Fulcrum Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-022910

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.